On rereading the announcement the scope for multiple combinations are opened up with multiple trials. We already know there is the separate MDMA trial at Monash for PTSD with Dr Paul in charge. To merely say this our second string to the psycodelic arm of the business may be short selling it. Just a thought but one which may open other doors.
Ann: IHL - VR and psychedelic R&D program, page-64
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)